Advertisement
Canada markets close in 3 hours 18 minutes

  • S&P/TSX

    21,990.91
    +105.53 (+0.48%)
     

  • S&P 500

    5,108.48
    +60.06 (+1.19%)
     

  • DOW

    38,293.54
    +207.74 (+0.55%)
     

  • CAD/USD

    0.7314
    -0.0009 (-0.13%)
     

  • CRUDE OIL

    84.03
    +0.46 (+0.55%)
     

  • Bitcoin CAD

    87,077.92
    -638.58 (-0.73%)
     

  • CMC Crypto 200

    1,325.92
    -70.61 (-5.06%)
     

  • GOLD FUTURES

    2,347.80
    +5.30 (+0.23%)
     

  • RUSSELL 2000

    2,000.53
    +19.41 (+0.98%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,949.60
    +337.84 (+2.16%)
     

  • VOLATILITY

    15.21
    -0.16 (-1.04%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6837
    +0.0016 (+0.23%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

NervGen Pharma Grants Stock Options

Newsfile Corp.
·1 min read

Vancouver, British Columbia--(Newsfile Corp. - November 15, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 400,000 incentive stock options to directors of the Company exercisable at a price of $1.74 per share for a period of five years and that vest equally every three months over a one-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company's stock option plan.

About NervGen
NervGen is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The Company's initial target indications are spinal cord injury, Alzheimer's disease and multiple sclerosis. For more information, go to www.nervgen.com.

For further information, please contact:

ADVERTISEMENT

Huitt Tracey, Corporate Communications
htracey@nervgen.com
604.537.2094

Nancy Thompson, Vorticom Public Relations
nancyt@vorticom.com
212.532.2208

Follow NervGen on Twitter (@NervgenP), LinkedIn (NervGen Pharma Corp.), and Facebook (facebook.com/nervgen/) for the latest news on the Company.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/144445